Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 281-288

  Zeng, Li ^a   Wang, Bo ^a   Merillat, Sean A ^a   Minakawa, Eiko N ^b   Perkins, Matthew D ^c   Ramani, Biswarathan ^a   Tallaksen Greene, Sara J ^a   Costa, Maria do Carmo ^a   Albin, Roger L ^a,d   Paulson, Henry L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

^d VAAAHS   (United States)

Author keywords

Huntington's disease; Polyglutamine; SCA3; UBA; UBL; UBQLN2

Indexed keywords

ADAPTOR PROTEIN; ATAXIN 3; HUNTINGTIN; PROTEIN P62; UBIQUILIN 1; UBIQUILIN 2; UBIQUITIN; UNCLASSIFIED DRUG; ATXN3 PROTEIN, HUMAN; CELL CYCLE PROTEIN; HTT PROTEIN, HUMAN; NERVE PROTEIN; REPRESSOR PROTEIN; UBQLN2 PROTEIN, HUMAN; UBQLN2 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INCLUSION; CEREBELLUM; CONTROLLED STUDY; DISEASE ASSOCIATION; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOREACTIVITY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR DEGENERATION; STRATUM RADIATUM; ANIMAL; BRAIN; CELL NUCLEUS INCLUSION BODY; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; GENETICS; HEK293 CELL LINE; MACHADO JOSEPH DISEASE; METABOLISM; MUTATION; PATHOLOGY; TRANSGENIC MOUSE;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ATAXIN-3; BRAIN; CELL CYCLE PROTEINS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEK293 CELLS; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; INTRANUCLEAR INCLUSION BODIES; MACHADO-JOSEPH DISEASE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; REPRESSOR PROTEINS; UBIQUITINS;

EID: 84936857047     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.017     Document Type: Article

References (39)

1. Brettschneider J., et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol. 2012, 123:825-839.
2. Cemal C.K., et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum. Mol. Genet. 2002, 11:1075-1094.
3. Chai Y., et al. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:9310-9315.
4. Costa Mdo C., et al. Toward RNAi therapy for the polyglutamine disease Machado-Joseph disease. Mol. Ther. 2013, 21:1898-1908.
5. Deng H.X., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
6. Doi H., et al. Identification of ubiquitin-interacting proteins in purified polyglutamine aggregates. FEBS Lett. 2004, 571:171-176.
7. Gilpin K.M., et al. ALS-linked mutations in ubiquilin-2 or hnRNPA1 reduce interaction between ubiquilin-2 and hnRNPA1. Hum. Mol. Genet. 2015, 24:2565-2577.
8. Heir R., et al. The UBL domain of PLIC-1 regulates aggresome formation. EMBO Rep. 2006, 7:1252-1258.
9. Heng M.Y., et al. Early autophagic response in a novel knock-in model of Huntington disease. Hum. Mol. Genet. 2010, 19:3702-3720.
10. Kleijnen M.F., et al. The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. Mol. Cell 2000, 6:409-419.
11. Ko H.S., et al. Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains. FEBS Lett. 2004, 566:110-114.
12. Lee D.Y., Brown E.J. Ubiquilins in the crosstalk among proteolytic pathways. Biol. Chem. 2012, 393:441-447.
13. Lim P.J., et al. Ubiquilin and p97/VCP bind erasin, forming a complex involved in ERAD. J. Cell Biol. 2009, 187:201-217.
14. Lin C.H., et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum. Mol. Genet. 2001, 10:137-144.
15. Mah A.L., et al. Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation. J. Cell Biol. 2000, 151:847-862.
16. Mori F., et al. Ubiquilin immunoreactivity in cytoplasmic and nuclear inclusions in synucleinopathies, polyglutamine diseases and intranuclear inclusion body disease. Acta Neuropathol. 2012, 124:149-151.
17. Nijholt D.A., et al. Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr. Med. Chem. 2011, 18:2459-2476.
18. Nolle A., et al. Ubiquilin 2 is not associated with tau pathology. PLoS One 2013, 8:e76598.
19. Orr H.T., Zoghbi H.Y. Reversing neurodegeneration: a promise unfolds. Cell 2000, 101:1-4.
20. Osaka M., et al. Evidence of a link between ubiquilin 2 and optineurin in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014, 1617-1629.
21. Paulson H.L., et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997, 19:333-344.
22. Ramani B., et al. A knock-in mouse model of spinocerebellar ataxia type 3 exhibits prominent aggregate pathology and aberrant splicing of the disease gene transcript. Hum. Mol. Genet. 2014, 1211-1224.
23. Rothenberg C., et al. Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. Hum. Mol. Genet. 2010, 19:3219-3232.
24. Rubinsztein D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443:780-786.
25. Rutherford N.J., et al. Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions. Brain Res. 2013, 1524:62-73.
26. Safren N., et al. Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease. PLoS One 2014, 9:e87513.
27. Safren N., et al. Signature changes in ubiquilin expression in the R6/2 mouse model of Huntington's disease. Brain Res. 2015, 1597:37-46.
28. Satoh J., et al. Ubiquilin-1 immunoreactivity is concentrated on Hirano bodies and dystrophic neurites in Alzheimer's disease brains. Neuropathol. Appl. Neurobiol. 2013, 39:817-830.
29. Stieren E.S., et al. Ubiquilin-1 is a molecular chaperone for the amyloid precursor protein. J. Biol. Chem. 2011, 286:35689-35698.
30. Viswanathan J., et al. Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formation. Traffic 2011, 12:330-348.
31. Walters K.J., et al. Structural studies of the interaction between ubiquitin family proteins and proteasome subunit S5a. Biochemistry 2002, 41:1767-1777.
32. Wang H., Monteiro M.J. Ubiquilin interacts and enhances the degradation of expanded-polyglutamine proteins. Biochem. Biophys. Res. Commun. 2007, 360:423-427.
33. Wang H., et al. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum. Mol. Genet. 2006, 15:1025-1041.
34. Wu A.L., et al. Ubiquitin-related proteins regulate interaction of vimentin intermediate filaments with the plasma membrane. Mol. Cell 1999, 4:619-625.
35. Yang H., et al. Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin. Exp. Cell Res. 2007, 313:538-550.
36. Zeng L., et al. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells. FEBS J. 2012, 279:2467-2478.
37. Zeng L., et al. The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease. J. Huntingt. Dis. 2013, 2:201-215.
38. Zhang C., Saunders A.J. An emerging role for ubiquilin 1 in regulating protein quality control system and in disease pathogenesis. Discov. Med. 2009, 8:18-22.
39. Zhang K.Y., et al. Ubiquilin 2: a component of the ubiquitin-proteasome system with an emerging role in neurodegeneration. Int. J. Biochem. Cell Biol. 2014, 50:123-126.